What evidence does Goldman Sachs provide that hedge funds are significantly increasing their exposure to US healthcare stocks?

Goldman Sachs reported that hedge fund exposure to the healthcare sector relative to U.S. equities hovered near a five-year high last week — the second consecutive week of increased sector allocation — and noted that funds ramped up purchases specifically in healthcare equipment and supplies, life sciences tools, and pharmaceuticals.

According to the news, what are the key catalysts driving hedge fund interest in healthcare stocks?

Goldman Sachs cited AI-driven breakthroughs in drug discovery, rising research productivity, projected M&A deal volumes of $173 billion in 2026 (the highest since 2019), and a record number of FDA new drug approvals in 2025 — the highest since 2020 — as primary catalysts; additionally, Trium Capital’s Felix Lo highlighted increased regulatory volatility and smaller pharma firms accepting higher discounts for deal certainty, creating a robust M&A environment.

Hedge Funds Bet on Rising US Healthcare Stocks Near 5-Year High, Says Goldman Sachs

Jul 27, 2026

Goldman Sachs reports hedge funds are increasing exposure to US healthcare stocks near five-year highs, driven by AI-driven drug discovery breakthroughs and favorable financing conditions. The sector sees record M&A deal volumes projected for 2026 alongside expedited FDA approvals.

reuters

2026-07-27

Hedge Funds Bet on Rising US Healthcare Stocks Near 5-Year High, Says Goldman Sachs

Hedge Funds Bet on Rising US Healthcare Stocks Near 5-Year High, Says Goldman Sachs

FAQ